Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INCA33890 · 2 trials · 4 indications
Defined as the time from the date of randomization to the date of the first documented progression as determined by the investigator per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 or death due to any cause.
| Arm | Type | Description |
|---|---|---|
| INCA33890 | EXPERIMENTAL | INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose. |
| Placebo | PLACEBO_COMPARATOR | Placebo will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose. |
| Part 1a - Dose Escalation Monotherapy | EXPERIMENTAL | INCA33890 will be administered at the protocol-defined dose based on cohort assignment. |
| Part 1b-Dose Expansion Monotherapy | EXPERIMENTAL | INCA33890 will be administered at the protocol-defined dose based on cohort assignment. |
| Part 2a - Dose Escalation Combination Therapy - Group 1 | EXPERIMENTAL | INCA33890 will be administered in combination with bevacizumab at the protocol-defined dose based on cohort assignment. |
| Part 2a - Dose Escalation Combination Therapy - Group 2 | EXPERIMENTAL | INCA33890 will be administered in combination with bevacizumab and FOLFIRI at the protocol-defined dose based on cohort assignment. |
| Part 2a - Dose Escalation Combination Therapy - Group 3 | EXPERIMENTAL | INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose based on cohort assignment. |
| Part 2a - Dose Escalation Combination Therapy - Group 4 | EXPERIMENTAL | INCA33890 will be administered in combination with cetuximab at the protocol-defined dose based on cohort assignment. |
| Part 2b - Dose Expansion Combination Therapy - Group 1 | EXPERIMENTAL | INCA33890 will be administered in combination with bevacizumab at the protocol-defined dose based on cohort assignment. |
| Part 2b - Dose Expansion Combination Therapy - Group 2 | EXPERIMENTAL | INCA33890 will be administered in combination with bevacizumab and FOLFIRI at the protocol-defined dose based on cohort assignment. |
| Part 2b - Dose Expansion Combination Therapy - Group 3 | EXPERIMENTAL | INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose based on cohort assignment. |
| Part 2b - Dose Expansion Combination Therapy - Group 4 | EXPERIMENTAL | INCA33890 will be administered in combination with cetuximab at the protocol-defined dose based on cohort assignment. |
| Name | Type | Description |
|---|---|---|
| INCA33890 | DRUG | INCA33890 will be administered at protocol defined dose. |
| Placebo | DRUG | Placebo will be administered at protocol defined dose. |
| Bevacizumab | DRUG | Bevacizumab will be administered at protocol defined dose. |
| FOLFOX | DRUG | FOLFOX will be administered at protocol defined dose. |
| FOLFIRI | DRUG | FOLFIRI will be administered at protocol defined dose. |
| Cetuximab | DRUG | Cetuximab will be administered at protocol defined dose. |
Inclusion Criteria: * Stage IV colorectal adenocarcinoma not amenable to curative resection. * No prior systemic treatment for unresectable or metastatic disease. Participants who received adjuvant or neoadjuvant therapy may enroll if there was no recurrence within 12 months of the end of treatment...
Top 20 of 81 competitors